Regeneron slams the brakes on rare disease trial following patient deaths — casting more doubt on a drug with mixed results
Hit with dual setbacks on Friday, Regeneron disclosed that the Covid-19 trial wasn’t the only program where it’s halting enrollment. The New York-based biotech has also hit the brakes on a study for fibrodysplasia ossificans progressiva after reports of patient deaths.
Regeneron didn’t disclose how many patients died and said they are investigating whether the deaths are related to garetosmab. But the serious adverse events that turned fatal were reported during the open-label extension period, when all patients were on treatment.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.